Adipose tissue and metabolic syndrome: Too much, too little or neither

European Journal of Clinical Investigation

Volumn 45, Issue 11, 2015, Pages 1209-1217

  Grundy, Scott M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Adipose tissue; Ectopic fat; Insulin resistance; Metabolic syndrome; Obesity; Overnutrition

Indexed keywords

FAT; FATTY ACID; ADIPOCYTOKINE;

ADIPOCYTE; ADIPOSE TISSUE; CALORIC INTAKE; ENERGY CONSUMPTION; HUMAN; LIPID STORAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OVERNUTRITION; PRIORITY JOURNAL; REVIEW; ANIMAL; BODY FAT DISTRIBUTION; DYSLIPIDEMIA; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER; METABOLISM; SKELETAL MUSCLE;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; BODY FAT DISTRIBUTION; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER; METABOLIC SYNDROME X; MUSCLE, SKELETAL; OBESITY;

EID: 84945487597     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12519     Document Type: Review

References (142)

1. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-36.
2. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007;92:399-404.
3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
4. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66, 155 cases and 91, 307 controls. Lancet 2006;367:651-8.
5. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379:1205-13.
6. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
7. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003;163:427-36.
8. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004;350:1220-34.
9. Garg A, Misra A. Lipodystrophies: rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004;33:305-31.
10. Decaudain A, Vantyghem MC, Guerci B, Hécart AC, Auclair M, Reznik Y et al. New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. J Clin Endocrinol Metab 2007;92:4835-44.
11. Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol 2010;207:245-55.
12. Savage DB. Mouse models of inherited lipodystrophy. Dis Model Mech 2009;2:554-62.
13. Vernochet C, Damilano F, Mourier A, Bezy O, Mori MA, Smyth G et al. Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications. FASEB J 2014;28:4408-19.
14. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117:2621-37.
15. Johnson PR, Hirsch J. Cellularity of adipose depots in six strains of genetically obese mice. J Lipid Res 1972;13:2-11.
16. Björntorp P, Bengtsson C, Blohmé G, Jonsson A, Sjöström L, Tibblin E et al. Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism 1971;20:927-35.
17. Drolet R, Richard C, Sniderman AD, Mailloux J, Fortier M, Huot C et al. Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond) 2008;32:283-91.
18. Salans LB, Cushman SW, Weismann RE. Studies of human adipose tissue. Adipose cell size and number in nonobese and obese patients. J Clin Invest 1973;52:929-41.
19. Sjostrom L, Björntorp P. Body composition and adipose cellularity in human obesity. Acta Med Scand 1974;195:201-11.
20. Lundgren M, Svensson M, Lindmark S, Renstrom F, Ruge T, Eriksson JW. Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia 2007;50:625-33.
21. Yang J, Eliasson B, Smith U, Cushman SW, Sherman AS. The size of large adipose cells is a predictor of insulin resistance. Obesity (Silver Spring) 2012;20:932-8.
22. Chandalia M, Lin P, Seenivasan T, Livingston EH, Snell PG, Grundy SM et al. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. PLoS ONE 2007;2:e812.
23. McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C et al. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia 2007;50:1707-15.
24. McLaughlin T, Lamendola C, Coghlan N, Liu TC, Lerner K, Sherman A et al. Subcutaneous adipose cell size and distribution: relationship to insulin resistance and body fat. Obesity (Silver Spring) 2014;22:673-80.
25. Balakrishnan P, Grundy SM, Islam A, Dunn F, Vega GL. Influence of upper and lower body adipose tissue on insulin sensitivity in South Asian men. J Investig Med 2012;60:999-1004.
26. McKeigue PM, Marmot MG, Syndercombe Court YD, Cottier DE, Rahman S et al. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. Br Heart J 1988;60:390-6.
27. Mather HM, Keen H. The Southall Diabetes Survey: prevalence of known diabetes in Asians and Europeans. Br Med J 1985;291:1081-4.
28. Abate N, Chandalia M, Snell PG, Grundy SM. Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. J Clin Endocrinol Metab 2004;89:2750-5.
29. Kursawe R, Eszlinger M, Narayan D, Liu T, Bazuine M, Cali AM et al. Cellularity and adipogenic profile of the abdominal subcutaneous adipose tissue from obese adolescents: association with insulin resistance and hepatic steatosis. Diabetes 2010;59:2288-96.
30. Abate N, Burns D, Peshock RM, Garg A, Grundy SM. Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res 1994;35:1490-6.
31. Vega GL, Adams-Huet B, Peshock R, Willett D, Shah B, Grundy SM. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab 2006;91:4459-66.
32. Grundy SM, Neeland IJ, Turer AT, Vega GL. Waist circumference as measure of abdominal fat compartments. J Obes 2013;2013:454285.
33. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-43.
34. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.
35. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(11 Suppl 1):S57-63.
36. Björntorp P. Visceral obesity: a "civilization syndrome". Obes Res 1993;1:206-22.
37. Cefalu WT, Wang ZQ, Webel S, Bell-Farrow A, Crouse JR, Hinson WH. Contribution of visceral fat mass to the insulin resistance of aging. Metabolism 1995;44:954-9.
38. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990;39:897-901.
39. Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an independent predictor of all-cause mortality in men. Obesity 2006;14:336-42.
40. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011;18:629-39.
41. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013;93:359-404.
42. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995;96:88-98.
43. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579-85.
44. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol 2000;278:E941-8.
45. Sites CK, Calles-Escandon J, Brochu M, Butterfield M, Ashikaga T, Poehlman ET. Relation of regional fat distribution to insulin sensitivity in postmenopausal women. Fertil Steril 2000;73:61-5.
46. Rendell M, Hulthen UL, Tornquist C, Groop L, Mattiasson I. Relationship between abdominal fat compartments and glucose and lipid metabolism in early postmenopausal women. J Clin Endocrinol Metab 2001;86:744-9.
47. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 h in patients with NIDDM. Diabetes 1988;37:1020-4.
48. Golay A, Swislocki AL, Chen YD, Jaspan JB, Reaven GM. Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone, and glucagon concentrations. J Clin Endocrinol Metab 1986;63:481-4.
49. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3-10.
50. Heptulla R, Smitten A, Teague B, Tamborlane WV, Ma Y-Z, Caprio S. Temporal patterns of circulating leptin levels in lean and obese adolescents: relationships to insulin, growth hormone, and free fatty acids rhythmicity. J Clin Endocrinol Metab 2001;86:90-6.
51. Boden G. Obesity and free fatty acids (FFA). Endocrinol Metab Clin North Am 2008;37:635-46.
52. Frayn KN, Williams CM, Arner P. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin Sci (Lond) 1996;90:243-53.
53. Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). Eur J Clin Invest 2000;30:45-52.
54. Bickerton AS, Roberts R, Fielding BA, Tornqvist H, Blaak EE, Wagenmakers AJ. Adipose tissue fatty acid metabolism in insulin-resistant men. Diabetologia 2008;51:1466-74.
55. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989;83:1168-73.
56. Guo ZK, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999;48:1586-92.
57. Nielsen S, Guo ZK, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582-8.
58. Roust LR, Jensen MD. Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes 1993;42:1567-73.
59. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007;46:716-22.
60. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49:791-801.
61. Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship with Cardiometabolic Risk/Intra-Abdominal Adiposity. Am J Clin Nutr 2012;96:714-26.
62. Ryo M, Kishida K, Nakamura T, Yoshizumi T, Funahashi T, Shimomura I. Clinical significance of visceral adiposity assessed by computed tomography: a Japanese perspective. World J Radiol 2014;6:409-16.
63. Karpe F, Pinnick KE. Biology of upper-body and lower-body adipose tissue-link to whole-body phenotypes. Nat Rev Endocrinol 2015;11:90-100.
64. Terry RB, Stefanick ML, Haskell WL, Wood PD. Contribution of regional adipose tissue depots to plasma lipoprotein concentrations in overweight men and women: possible protective effects of thigh fat. Metabolism 1991;40:733-40.
65. Sjostrom CD, Hakangard AC, Lissner L, Sjostrom L. Body compartment and subcutaneous adipose tissue distribution-risk factor patterns in obese subjects. Obes Res 1995;3:9-22.
66. Seidell JC, Perusse L, Despres J-P, Bouchard C. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr 2001;74:315-21.
67. Tankó LB, Bagger YZ, Alexandersen P, Christiansen C. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003;107:1626-31.
68. Manolopoulos KN, Karpe F, Frayn KN. Marked resistance of femoral adipose tissue blood flow and lipolysis to adrenaline in vivo. Diabetologia 2012;55:3029-37.
69. Pinnick KE, Nicholson G, Manolopoulos KN, McQuaid SE, Valet P, Frayn KN et al. Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 2014;63:3785-97.
70. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015;125:1790-2.
71. Tuvdendorj D, Chandalia M, Batbayar T, Saraf M, Beysen C, Murphy EJ et al. Altered subcutaneous abdominal adipose tissue lipid synthesis in obese, insulin-resistant humans. Am J Physiol Endocrinol Metab 2013;305:E999-1006.
72. Shadid S, Koutsari C, Jensen MD. Direct free fatty acid uptake into human adipocytes in vivo: relation to body fat distribution. Diabetes 2007;56:1369-75.
73. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011;60:2441-9.
74. Nelson RH, Basu R, Johnson CM, Rizza RA, Miles JM. Splanchnic spillover of extracellular lipase-generated fatty acids in overweight and obese humans. Diabetes 2007;56:2878-84.
75. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014;510:84-91.
76. Howard BV, Zech L, Davis M, Bennion LJ, Savage PJ, Nagulesparan M et al. Studies of very low density lipoprotein triglyceride metabolism in an obese population with low plasma lipids: lack of influence of body weight or plasma insulin. J Lipid Res 1980;21:1032-41.
77. Grundy SM, Mok HY, Zech L, Steinberg D, Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest 1979;63:1274-83.
78. Lillioja S, Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 1988;4:517-40.
79. Tulloch-Reid MK, Williams DE, Looker HC, Hanson RL, Knowler WC. Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care 2003;26:2556-61.
80. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51.
81. Barrows BR, Timlin MT, Parks EJ. Spillover of dietary fatty acids and use of serum nonesterified fatty acids for the synthesis of VLDL-triacylglycerol under two different feeding regimens. Diabetes 2005;54:2668-73.
82. Almandoz JP, Singh E, Howell LA, Grothe K, Vlazny DT, Smailovic A et al. Spillover of fatty acids during dietary fat storage in type 2 diabetes: relationship to body fat depots and effects of weight loss. Diabetes 2013;62:1897-903.
83. McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM. Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes 2011;60:47-55.
84. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003;77:43-50.
85. Ahrens EH Jr, Hirsch J, Oette K, Farquhar JW, Stein Y. Carbohydrate-induced and fat-induced lipemia. Trans Assoc Am Physicians 1961;74:134-46.
86. Grundy SM. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. N Engl J Med 1986;314:745-8.
87. Garg A, Grundy SM, Unger RH. Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes 1992;41:1278-85.
88. Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 2012;6:91-101.
89. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49.
90. Friedman JM, Mantzoros CS. 20 years of leptin: from the discovery of the leptin gene to leptin in our therapeutic armamentarium. Metabolism 2015;64:1-4.
91. Montaque CT, Farooqi S, Whitehead JP, Soos MA, Rau H, Wareham NJ et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903-8.
92. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;392:398-401.
93. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-61.
94. Flier JS. Clinical review 94: what's in a name? In search of leptin'sphysiologic role. J Clin Endocrinol Metab 1998;83:1407-13.
95. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-8.
96. Nakamura Y, Ueshima H, Okuda N, Murakami Y, Miura K, Kita Y et al. Serum leptin and total dietary energy intake: the INTERLIPID Study. Eur J Nutr 2013;52:1641-8.
97. DePaoli AM. 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J Endocrinol 2014;223:T71-81.
98. Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 2003;3:207-13.
99. Bueno AC, Sun K, Martins CS, Elias J Jr, Miranda W, Tao C et al. A novel ADIPOQ mutation (p. M40K) impairs assembly of high-molecular-weight adiponectin and is associated with early-onset obesity and metabolic syndrome. J Clin Endocrinol Metab 2014;99:E683-93.
100. Sandy An S, Palmer ND, Hanley AJ, Ziegler JT, Mark Brown W, Freedman BI et al. Genetic analysis of adiponectin variation and its association with type 2 diabetes in African Americans. Obesity (Silver Spring) 2013;21:E721-9.
101. Cao D, Ouyang S, Liu Z, Ma F, Wu J. Association of the ADIPOQ T45G polymorphism with insulin resistance and blood glucose: a meta-analysis. Endocr J 2014;61:437-46.
102. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
103. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
104. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 2012;15:635-45.
105. Chang C, Garcia-Garcia AB, Hamilton E, Shah B, Meguro S, Grundy SM et al. Metabolic syndrome phenotype in very obese women. Metab Syndr Relat Disord 2007;5:3-12.
106. Khera A, Vega GL, Das SR, Ayers C, McGuire DK, Grundy SM et al. Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab 2009;94:3251-8.
107. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 2013;21:E439-47.
108. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
109. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
110. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25. Review.
111. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207.
112. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-7.
113. Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, Fina F, Sentocnik JT et al. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001;44:2025-31.
114. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63.
115. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infraction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-7.
116. Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP. Body mass index and blood pressures in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 1994;12:1433-7.
117. Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987;16:234-51.
118. Reaven GM. Relationship between insulin resistance and hypertension. Diabetes Care 1991;14:33-8.
119. Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep 2000;2:139-47.
120. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010;285:17271-6.
121. Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM et al. Leptin mediates the increase in blood pressure associated with obesity. Cell 2014;159:1404-16.
122. Rojas E, Rodríguez-Molina D, Bolli P, Israili ZH, Faría J, Fidilio E et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep 2014;16:463.
123. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-51.
124. Welle S, Forbes GB, Statt M, Barnard RR, Amatruda JM. Energy expenditure under free-living conditions in normal-weight and overweight women. Am J Clin Nutr 1992;55:14-21.
125. Swinburn BA, Sacks G, Lo SK, Westerterp KR, Rush EC, Rosenbaum M et al. Estimating the changes in energy flux that characterize the rise in obesity prevalence. Am J Clin Nutr 2009;89:1723-8.
126. Forbes GB. The companionship of lean and fat. In: Ellis KJ, Eastman JD, editors. Human Body Composition. New York, NY: Plenum Press; 1993: pp 3-14.
127. Albu JB, Kovera AJ, Allen L, Wainwright M, Berk E, Raja-Khan N et al. Independent association of insulin resistance with larger amounts of intermuscular adipose tissue and a greater acute insulin response to glucose in African American than in white nondiabetic women. Am J Clin Nutr 2005;82:1210-7.
128. Leon B, Jenkins S, Pepin K, Chaudhry H, Smith K, Zalos G et al. Insulin and extremity muscle mass in overweight and obese women. Int J Obes (Lond) 2013;37:1560-4.
129. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014;371:1131-41.
130. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37. Review. Erratum in: JAMA. 2005;293:1728.
131. Clifton PM. Bariatric surgery: results in obesity and effects on metabolic parameters. Curr Opin Lipidol 2011;22:1-5.
132. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
133. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-9.
134. Goldberg RB, Mather K. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. Arterioscler Thromb Vasc Biol 2012;32:2077-90.
135. Ruderman NB, Schneider SH, Berchtold P. The, "metabolically-obese", normal-weight individual. Am J Clin Nutr 1981;34:1617-21.
136. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007;104:12587-94.
137. Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr 2010;30:273-90.
138. Altinli S, Elevli M, Ozkul AA, Kara PG, Karsidag K, Dogru M. Insulin resistance and metabolic syndrome in children of parents with diabetes mellitus. J Pediatr Endocrinol Metab 2007;20:431-6.
139. Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009;7:497-514.
140. Skoumas J, Papadimitriou L, Pitsavos C, Masoura C, Giotsas N, Chrysohoou C et al. Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia. Metabolism 2007;56:135-41.
141. Grundy SM, Neeland IJ, Turer AT, Vega GL. Ethnic and gender susceptibility to metabolic risk. Metab Syndr Relat Disord 2014;12:110-6.
142. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006;5:295-309.